Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients
Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease. However, the extent of proton pump inhibitor prescriptions to chronic kidney disease patients is still unclear. In a retrospective study, we enrolled patients...
Gespeichert in:
| Veröffentlicht in: | PloS one 2018-09, Vol.13 (9), p.e0203878-e0203878 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0203878 |
|---|---|
| container_issue | 9 |
| container_start_page | e0203878 |
| container_title | PloS one |
| container_volume | 13 |
| creator | Lee, Hee Jeong Lee, Haekyung Oh, Song Hee Park, Joonbyung Park, Suyeon Jeon, Jin Seok Noh, HyunJin Han, Dong Cheol Kwon, Soon Hyo |
| description | Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease. However, the extent of proton pump inhibitor prescriptions to chronic kidney disease patients is still unclear.
In a retrospective study, we enrolled patients (>18 years old) who received proton pump inhibitor in the out-patient setting from 2014 through 2015. All data was obtained from electronical medical records of Soonchunhyang Medical Center. The prescription patterns and characteristics of proton pump inhibitors were analyzed according to individual estimated glomerular filtration rate of the patients.
During the study period 178,228 patients visited the out-patient clinic. Proton pump inhibitors were prescribed to 9,109 (5.11%) patients. In our sample, 50% were females and 9.8% were chronic kidney disease (eGFR |
| doi_str_mv | 10.1371/journal.pone.0203878 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2103695559</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ce171c1d73e64747a27309e43345e716</doaj_id><sourcerecordid>2105065377</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-33b620f96f5516872a48c501c27ab9c33013f7586cb6238ea9f37f62aaeb8fb73</originalsourceid><addsrcrecordid>eNptUk2P0zAUjBCIXRb-AQJLXLqHFDsvtpMLEipfFSuxBzhbjvOydUnsYKeI_fe4bbbaRZzsZ8-MZ6zJspeMLhlI9nbrd8Hpfjl6h0taUKhk9Sg7ZzUUuUjj43v7s-xZjFtKOVRCPM3OgBasSMN5Fleb4J015KdtHd6S1kbUEcli9fXDJRn1ZNFNkeiABP-MPmJLJk8Gn-Yx-Mk7Mu6GkVi3sY2dfCCL6-v1ZSTGD2MiHdDOuzzJndSeZ0863Ud8Ma8X2Y9PH7-vvuRX3z6vV--vcsMLMeUATfLe1aLjnIlKFrqsDKfMFFI3tQGgDDrJK2ESDirUdQeyE4XW2FRdI-Eie33UHXsf1fxfURWMgqg553VCrI-I1uutGoMddLhVXlt1OPDhRukwWdOjMsgkM6yVgKKUpdSFBFpjCVBylEwkrXfza7tmwNakpEH3D0Qf3ji7UTf-txIMhJSQBBazQPC_dhgnNdhosO-1Q787-OZUcJD7ZG_-gf4_XXlEmeBjDNidzDCq9h26Y6l9h9TcoUR7dT_IiXRXGvgL8CzDpQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2103695559</pqid></control><display><type>article</type><title>Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Lee, Hee Jeong ; Lee, Haekyung ; Oh, Song Hee ; Park, Joonbyung ; Park, Suyeon ; Jeon, Jin Seok ; Noh, HyunJin ; Han, Dong Cheol ; Kwon, Soon Hyo</creator><contributor>Aguilera, Abelardo I.</contributor><creatorcontrib>Lee, Hee Jeong ; Lee, Haekyung ; Oh, Song Hee ; Park, Joonbyung ; Park, Suyeon ; Jeon, Jin Seok ; Noh, HyunJin ; Han, Dong Cheol ; Kwon, Soon Hyo ; Aguilera, Abelardo I.</creatorcontrib><description>Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease. However, the extent of proton pump inhibitor prescriptions to chronic kidney disease patients is still unclear.
In a retrospective study, we enrolled patients (>18 years old) who received proton pump inhibitor in the out-patient setting from 2014 through 2015. All data was obtained from electronical medical records of Soonchunhyang Medical Center. The prescription patterns and characteristics of proton pump inhibitors were analyzed according to individual estimated glomerular filtration rate of the patients.
During the study period 178,228 patients visited the out-patient clinic. Proton pump inhibitors were prescribed to 9,109 (5.11%) patients. In our sample, 50% were females and 9.8% were chronic kidney disease (eGFR<60mL/min/1.73 m2) patients. Among the patients with chronic kidney disease, 730 (8.0%) were categorized as stage 3 or 4 and 166 (1.8%) were categorized as stage 5 or end-stage renal disease. The prevalence of proton pump inhibitors prescription among chronic kidney disease patients was higher than in the non-chronic kidney disease group (p<0.001). Median duration of usage was 120 [interquartile range 63-273] days in the stage 3-4 group, 106 [56-266] days in the stage 5-end-stage renal disease group and 90 [56-176] days in the non-chronic kidney disease group. Patients in stage 3-4 group were prescribed longer duration of proton pump inhibitors than the non-chronic kidney disease group even after adjusting for age and sex (p<0.001). The main departments of medicine which prescribed proton pump inhibitors for the stage 3-4 group were gastroenterology (40.0%), cardiology (29.6%), nephrology (9.5%) and neurology (4.8%). Compared to the non-chronic kidney disease group, the stage 3-4 and stage 5-end-stage renal disease group were taking larger number of drugs simultaneously (6.90±4.17 vs4.54±2.43; p<0.001, 5.64±2.87 vs 4.54±2.34; p<0.001, respectively).
Chronic kidney disease patients are taking proton pump inhibitors for a much longer duration compared to non-chronic kidney disease patients. Physicians should pay careful attention when prescribing proton pump inhibitors to high risk groups.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0203878</identifier><identifier>PMID: 30212538</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Anticoagulants ; Biology and Life Sciences ; Cardiology ; Cardiovascular disease ; Chronic illnesses ; Drug dosages ; End-stage renal disease ; Epidermal growth factor receptors ; Females ; Gastroenterology ; Gastroesophageal reflux ; Glomerular filtration rate ; Health care facilities ; Hospitals ; Inhibitors ; Internal medicine ; Kidney diseases ; Kidneys ; Laboratories ; Medical electronics ; Medical personnel ; Medical records ; Medicine ; Medicine and Health Sciences ; Mortality ; Nephrology ; Neurology ; Patients ; People and Places ; Physicians ; Prescriptions ; Proton pump inhibitors ; Protons ; Risk groups ; Studies ; Ulcers</subject><ispartof>PloS one, 2018-09, Vol.13 (9), p.e0203878-e0203878</ispartof><rights>2018 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Lee et al 2018 Lee et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-33b620f96f5516872a48c501c27ab9c33013f7586cb6238ea9f37f62aaeb8fb73</citedby><cites>FETCH-LOGICAL-c526t-33b620f96f5516872a48c501c27ab9c33013f7586cb6238ea9f37f62aaeb8fb73</cites><orcidid>0000-0002-4114-4196</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136773/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136773/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30212538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Aguilera, Abelardo I.</contributor><creatorcontrib>Lee, Hee Jeong</creatorcontrib><creatorcontrib>Lee, Haekyung</creatorcontrib><creatorcontrib>Oh, Song Hee</creatorcontrib><creatorcontrib>Park, Joonbyung</creatorcontrib><creatorcontrib>Park, Suyeon</creatorcontrib><creatorcontrib>Jeon, Jin Seok</creatorcontrib><creatorcontrib>Noh, HyunJin</creatorcontrib><creatorcontrib>Han, Dong Cheol</creatorcontrib><creatorcontrib>Kwon, Soon Hyo</creatorcontrib><title>Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease. However, the extent of proton pump inhibitor prescriptions to chronic kidney disease patients is still unclear.
In a retrospective study, we enrolled patients (>18 years old) who received proton pump inhibitor in the out-patient setting from 2014 through 2015. All data was obtained from electronical medical records of Soonchunhyang Medical Center. The prescription patterns and characteristics of proton pump inhibitors were analyzed according to individual estimated glomerular filtration rate of the patients.
During the study period 178,228 patients visited the out-patient clinic. Proton pump inhibitors were prescribed to 9,109 (5.11%) patients. In our sample, 50% were females and 9.8% were chronic kidney disease (eGFR<60mL/min/1.73 m2) patients. Among the patients with chronic kidney disease, 730 (8.0%) were categorized as stage 3 or 4 and 166 (1.8%) were categorized as stage 5 or end-stage renal disease. The prevalence of proton pump inhibitors prescription among chronic kidney disease patients was higher than in the non-chronic kidney disease group (p<0.001). Median duration of usage was 120 [interquartile range 63-273] days in the stage 3-4 group, 106 [56-266] days in the stage 5-end-stage renal disease group and 90 [56-176] days in the non-chronic kidney disease group. Patients in stage 3-4 group were prescribed longer duration of proton pump inhibitors than the non-chronic kidney disease group even after adjusting for age and sex (p<0.001). The main departments of medicine which prescribed proton pump inhibitors for the stage 3-4 group were gastroenterology (40.0%), cardiology (29.6%), nephrology (9.5%) and neurology (4.8%). Compared to the non-chronic kidney disease group, the stage 3-4 and stage 5-end-stage renal disease group were taking larger number of drugs simultaneously (6.90±4.17 vs4.54±2.43; p<0.001, 5.64±2.87 vs 4.54±2.34; p<0.001, respectively).
Chronic kidney disease patients are taking proton pump inhibitors for a much longer duration compared to non-chronic kidney disease patients. Physicians should pay careful attention when prescribing proton pump inhibitors to high risk groups.</description><subject>Anticoagulants</subject><subject>Biology and Life Sciences</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Chronic illnesses</subject><subject>Drug dosages</subject><subject>End-stage renal disease</subject><subject>Epidermal growth factor receptors</subject><subject>Females</subject><subject>Gastroenterology</subject><subject>Gastroesophageal reflux</subject><subject>Glomerular filtration rate</subject><subject>Health care facilities</subject><subject>Hospitals</subject><subject>Inhibitors</subject><subject>Internal medicine</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Laboratories</subject><subject>Medical electronics</subject><subject>Medical personnel</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Mortality</subject><subject>Nephrology</subject><subject>Neurology</subject><subject>Patients</subject><subject>People and Places</subject><subject>Physicians</subject><subject>Prescriptions</subject><subject>Proton pump inhibitors</subject><subject>Protons</subject><subject>Risk groups</subject><subject>Studies</subject><subject>Ulcers</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNptUk2P0zAUjBCIXRb-AQJLXLqHFDsvtpMLEipfFSuxBzhbjvOydUnsYKeI_fe4bbbaRZzsZ8-MZ6zJspeMLhlI9nbrd8Hpfjl6h0taUKhk9Sg7ZzUUuUjj43v7s-xZjFtKOVRCPM3OgBasSMN5Fleb4J015KdtHd6S1kbUEcli9fXDJRn1ZNFNkeiABP-MPmJLJk8Gn-Yx-Mk7Mu6GkVi3sY2dfCCL6-v1ZSTGD2MiHdDOuzzJndSeZ0863Ud8Ma8X2Y9PH7-vvuRX3z6vV--vcsMLMeUATfLe1aLjnIlKFrqsDKfMFFI3tQGgDDrJK2ESDirUdQeyE4XW2FRdI-Eie33UHXsf1fxfURWMgqg553VCrI-I1uutGoMddLhVXlt1OPDhRukwWdOjMsgkM6yVgKKUpdSFBFpjCVBylEwkrXfza7tmwNakpEH3D0Qf3ji7UTf-txIMhJSQBBazQPC_dhgnNdhosO-1Q787-OZUcJD7ZG_-gf4_XXlEmeBjDNidzDCq9h26Y6l9h9TcoUR7dT_IiXRXGvgL8CzDpQ</recordid><startdate>20180913</startdate><enddate>20180913</enddate><creator>Lee, Hee Jeong</creator><creator>Lee, Haekyung</creator><creator>Oh, Song Hee</creator><creator>Park, Joonbyung</creator><creator>Park, Suyeon</creator><creator>Jeon, Jin Seok</creator><creator>Noh, HyunJin</creator><creator>Han, Dong Cheol</creator><creator>Kwon, Soon Hyo</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4114-4196</orcidid></search><sort><creationdate>20180913</creationdate><title>Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients</title><author>Lee, Hee Jeong ; Lee, Haekyung ; Oh, Song Hee ; Park, Joonbyung ; Park, Suyeon ; Jeon, Jin Seok ; Noh, HyunJin ; Han, Dong Cheol ; Kwon, Soon Hyo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-33b620f96f5516872a48c501c27ab9c33013f7586cb6238ea9f37f62aaeb8fb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anticoagulants</topic><topic>Biology and Life Sciences</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Chronic illnesses</topic><topic>Drug dosages</topic><topic>End-stage renal disease</topic><topic>Epidermal growth factor receptors</topic><topic>Females</topic><topic>Gastroenterology</topic><topic>Gastroesophageal reflux</topic><topic>Glomerular filtration rate</topic><topic>Health care facilities</topic><topic>Hospitals</topic><topic>Inhibitors</topic><topic>Internal medicine</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Laboratories</topic><topic>Medical electronics</topic><topic>Medical personnel</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Mortality</topic><topic>Nephrology</topic><topic>Neurology</topic><topic>Patients</topic><topic>People and Places</topic><topic>Physicians</topic><topic>Prescriptions</topic><topic>Proton pump inhibitors</topic><topic>Protons</topic><topic>Risk groups</topic><topic>Studies</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Hee Jeong</creatorcontrib><creatorcontrib>Lee, Haekyung</creatorcontrib><creatorcontrib>Oh, Song Hee</creatorcontrib><creatorcontrib>Park, Joonbyung</creatorcontrib><creatorcontrib>Park, Suyeon</creatorcontrib><creatorcontrib>Jeon, Jin Seok</creatorcontrib><creatorcontrib>Noh, HyunJin</creatorcontrib><creatorcontrib>Han, Dong Cheol</creatorcontrib><creatorcontrib>Kwon, Soon Hyo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Hee Jeong</au><au>Lee, Haekyung</au><au>Oh, Song Hee</au><au>Park, Joonbyung</au><au>Park, Suyeon</au><au>Jeon, Jin Seok</au><au>Noh, HyunJin</au><au>Han, Dong Cheol</au><au>Kwon, Soon Hyo</au><au>Aguilera, Abelardo I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2018-09-13</date><risdate>2018</risdate><volume>13</volume><issue>9</issue><spage>e0203878</spage><epage>e0203878</epage><pages>e0203878-e0203878</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease. However, the extent of proton pump inhibitor prescriptions to chronic kidney disease patients is still unclear.
In a retrospective study, we enrolled patients (>18 years old) who received proton pump inhibitor in the out-patient setting from 2014 through 2015. All data was obtained from electronical medical records of Soonchunhyang Medical Center. The prescription patterns and characteristics of proton pump inhibitors were analyzed according to individual estimated glomerular filtration rate of the patients.
During the study period 178,228 patients visited the out-patient clinic. Proton pump inhibitors were prescribed to 9,109 (5.11%) patients. In our sample, 50% were females and 9.8% were chronic kidney disease (eGFR<60mL/min/1.73 m2) patients. Among the patients with chronic kidney disease, 730 (8.0%) were categorized as stage 3 or 4 and 166 (1.8%) were categorized as stage 5 or end-stage renal disease. The prevalence of proton pump inhibitors prescription among chronic kidney disease patients was higher than in the non-chronic kidney disease group (p<0.001). Median duration of usage was 120 [interquartile range 63-273] days in the stage 3-4 group, 106 [56-266] days in the stage 5-end-stage renal disease group and 90 [56-176] days in the non-chronic kidney disease group. Patients in stage 3-4 group were prescribed longer duration of proton pump inhibitors than the non-chronic kidney disease group even after adjusting for age and sex (p<0.001). The main departments of medicine which prescribed proton pump inhibitors for the stage 3-4 group were gastroenterology (40.0%), cardiology (29.6%), nephrology (9.5%) and neurology (4.8%). Compared to the non-chronic kidney disease group, the stage 3-4 and stage 5-end-stage renal disease group were taking larger number of drugs simultaneously (6.90±4.17 vs4.54±2.43; p<0.001, 5.64±2.87 vs 4.54±2.34; p<0.001, respectively).
Chronic kidney disease patients are taking proton pump inhibitors for a much longer duration compared to non-chronic kidney disease patients. Physicians should pay careful attention when prescribing proton pump inhibitors to high risk groups.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>30212538</pmid><doi>10.1371/journal.pone.0203878</doi><orcidid>https://orcid.org/0000-0002-4114-4196</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2018-09, Vol.13 (9), p.e0203878-e0203878 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2103695559 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Anticoagulants Biology and Life Sciences Cardiology Cardiovascular disease Chronic illnesses Drug dosages End-stage renal disease Epidermal growth factor receptors Females Gastroenterology Gastroesophageal reflux Glomerular filtration rate Health care facilities Hospitals Inhibitors Internal medicine Kidney diseases Kidneys Laboratories Medical electronics Medical personnel Medical records Medicine Medicine and Health Sciences Mortality Nephrology Neurology Patients People and Places Physicians Prescriptions Proton pump inhibitors Protons Risk groups Studies Ulcers |
| title | Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T11%3A13%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20kidney%20disease%20(CKD)%20patients%20are%20exposed%20to%20more%20proton%20pump%20inhibitor%20(PPI)s%20compared%20to%20non-CKD%20patients&rft.jtitle=PloS%20one&rft.au=Lee,%20Hee%20Jeong&rft.date=2018-09-13&rft.volume=13&rft.issue=9&rft.spage=e0203878&rft.epage=e0203878&rft.pages=e0203878-e0203878&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0203878&rft_dat=%3Cproquest_plos_%3E2105065377%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2103695559&rft_id=info:pmid/30212538&rft_doaj_id=oai_doaj_org_article_ce171c1d73e64747a27309e43345e716&rfr_iscdi=true |